21st May 2018 13:24
LONDON (Alliance News) - Omega Diagnostics Group PLC on Monday confirmed that results from feasibility testing of its Visitect CD4 test for identifying advanced HIV disease showed "acceptable" performance against design goals.
The medical diagnostics company said that it recently held a design review meeting for its Visitect CD4 product after its recently announced restructuring plan.
Back in mid-April, Omega Diagnostics said it plans to simplify the business to significantly reduce its cost base.
As a result, the company focused on Visitect CD4, Allersys and food intolerance products while closing its German allergy business and manufacturing site in Pune, India.
Following the positive Visitect CD4 trial results, Omega Diagnostics said it has progressed into a formal optimisation phase within its design control programme.
"I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications," said Chief Executive Colin King. "I look forward to making further announcements as we bring this product to market."
Shares in Omega Diagnostics were trading 0.8% higher at 12.60 pence each on Monday.
Related Shares:
ODX.L